Palbociclib Improves PFS in ER-Positive, HER2-Negative Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, palbociclib significantly improved progression-free survival when combined with letrozole in patients with advanced estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

For the phase 2 study, researchers enrolled 165 patients with advanced ER-positive, HER2-negative breast cancer and randomly assigned them to receive letrozole 2.5mg orally daily with or without palbociclib 125mg orally daily for 3 weeks of each 28-day cycle.

Results showed that median progression-free survival was 20.2 months (95% CI: 13.8 - 27.5) for the combination arm and 27.9 months (95% CI: 25.5 - 31.1) for the letrozole arm (HR = 0.488; 95% CI: 0.319 - 0.748; one-sided P = 0.0004). In regard to safety, 54% of patients assigned to the palbociclib arm experienced grade 3-4 neutropenia compared with only 1% of those in the letrozole group.

In addition, 19% of those that received palbociclib experienced grade 3-4 leukopenia and 4% experienced grade 3-4 fatigue versus 0% and 1% in the letrozole alone group, respectively. No patients experienced febrile neutropenia.

Palbociclib Improves PFS in ER-Positive, HER2-Negative Breast Cancer
Palbociclib significantly improved progression-free survival when combined with letrozole.
The addition of palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast cancer. A phase 3 trial is currently underway.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs